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The recently discovered nucleotide binding domain-leucine rich repeat (NLR) gene family is conserved from
plants to mammals, and several members are associated with human autoinflammatory or immunodeficiency
disorders. This family is defined by a central nucleotide binding domain that contains the highly conserved
Walker A and Walker B motifs. Although the nucleotide binding domain is a defining feature of this family, it
has not been extensively studied in its purified form. In this report, we show that purified Monarch-1/NLRP12,
an NLR protein that negatively regulates NF-B signaling, specifically binds ATP and exhibits ATP hydrolysis
activity. Intact Walker A/B motifs are required for this activity. These motifs are also required for Monarch-1
to undergo self-oligomerization, Toll-like receptor- or CD40L-activated association with NF-B-inducing
kinase (NIK) and interleukin-1 receptor-associated kinase 1 (IRAK-1), degradation of NIK, and inhibition of
IRAK-1 phosphorylation. The stable expression of a Walker A/B mutant in THP-1 monocytes results in
increased production of proinflammatory cytokines and chemokines to an extent comparable to that in cells in
which Monarch-1 is silenced via short hairpin RNA. The results of this study are consistent with a model
wherein ATP binding regulates the anti-inflammatory activity of Monarch-1.
Nucleotide binding domain-leucine rich repeat (NLR) pro-
teins share strong structural homology to the largest subgroup
of plant disease resistance (R) proteins. These proteins share a
trimeric domain architecture consisting of an N-terminal ef-
fector domain, a central nucleotide binding domain (NBD),
and C-terminal leucine rich repeats (LRR). Mounting evi-
dence suggests that NLR genes are important for the host
response to pathogens and the regulation of inflammation.
Interest in these genes has been further propelled by the re-
alization that mutations in certain NLR genes are linked to
human autoinflammatory and immunodeficiency diseases. For
example, mutations in CIITA, the major histocompatability
complex (MHC) class II transactivator, lead to a severe immu-
nodeficiency disease, bare lymphocyte syndrome (22). Muta-
tions in NOD2/CARD15 are associated with Crohn’s disease
and Blau syndrome, two human disorders with hyperinflam-
matory manifestations (3, 7, 18, 20). Finally, mutations in the
cold-induced autoinflammatory syndrome-1 gene (CIAS1, also
NALP3) are associated with a spectrum of autoinflammatory
disorders which likely represent similar diseases with various
levels of severity: familial cold-induced autoinflammatory syn-
drome, Muckle-Wells syndrome, and neonatal-onset multisys-
tem inflammatory disease/chronic infantile neurologic, cutane-
ous, articular syndrome (1, 5, 8, 16, 19). Most notably, the
majority of known disease-associated mutations within these
NLR genes reside within the NBD domain. However, the in-
fluence of these mutations on the nucleotide binding activity
remains poorly understood.
Several recent studies have provided greater detail regarding
the mechanism and biological significance of nucleotide binding
by NLR and NLR-related proteins. Apoptotic protease activating
factor-1 (APAF-1) is a protein that contains a central NBD and
C-terminal WD-40 repeats and thus is closely related to the NLR
family. Under apoptotic conditions, APAF-1 binds cytochrome c.
This interaction stimulates APAF-1 binding to dATP, leading to
the formation of an APAF-1 heptamer that activates caspase-9.
Thus, dATP binding by APAF-1 is a key regulatory step in the
apoptotic process (6, 10). Similar to APAF-1, the NLR protein
NLRP3 (previously known as cryopyrin, CIAS1, or NALP3) also
requires nucleotide binding for its activity. Our group has recently
demonstrated that, in the absence of a functional NBD, NLRP3
cannot form an active inflammasome. This results in reduced
interleukin-1 (IL-1) processing and decreased cell death (4).
Most importantly, inactivation of the NBD of NLRP3 abolishes
the hyperreactive phenotype of naturally occurring disease-asso-
ciated mutations of this NLR protein. This demonstrates that
nucleotide binding is required for the inflammatory phenotype of
NLRP3-linked diseases.
In light of these findings, we examined the contribution of
nucleotide binding to the functional role of an NLR protein,
Monarch-1/NLRP12. Monarch-1 is expressed predominantly
in cells of the myeloid lineage, including monocytes and gran-
ulocytes (28). Furthermore, single nucleotide polymorphism
analysis has recently demonstrated a genetic link between
Monarch-1 and atopic dermatitis (15). However, in contrast to
most NLR proteins that promote inflammation, Monarch-1
functions as an attenuator of inflammatory responses. Mon-
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arch-1 inhibits Toll-like receptor (TLR)-mediated hyperphos-
phorylation of IL-1 receptor-associated kinase 1 (IRAK-1), a
necessary step in IRAK-1 signaling pathways (27). In addition,
Monarch-1 binds to and destabilizes the mitogen-activated
protein kinase kinase kinase NF-B-inducing kinase (NIK)
and blocks NIK-mediated processing of NF-B2/p100 to p52
(12). The p52 subunit is an important downstream mediator of
signaling by TLRs as well as tumor necrosis factor family re-
ceptors, including CD40 and lymphotoxin-beta receptor. The
introduction of short hairpin RNA (shRNA) specific for Mon-
arch-1 greatly enhances NF-B activation and the transcription
of NIK-dependent genes induced by TLR and/or tumor necro-
sis factor family receptor activation (12). These earlier studies
suggest that Monarch-1 performs an important anti-inflamma-
tory role as an inhibitory molecule of innate immune activa-
tion.
In this report, we explore the role of nucleotide binding in
the anti-inflammatory activity of Monarch-1. Herein, we dem-
onstrate that Monarch-1, purified to homogeneity, specifically
binds ATP. Nucleotide binding is indispensable for the biolog-
ical function of Monarch-1, as an NBD mutant form of Mon-
arch-1 does not inhibit IRAK-1 hyperphosphorylation nor
does it inhibit NIK-dependent p52 production. Moreover,
THP-1 monocytes stably expressing the NBD mutant form of
Monarch-1 secrete elevated levels of proinflammatory cyto-
kines and chemokines. These results open the door for the
characterization of the nucleotide binding properties of other
NLR members and will facilitate the design of pharmacologi-
cal agents that modulate the functions of this family of pro-
teins.
MATERIALS AND METHODS
Reagents. The TLR2 agonist, the synthetic lipoprotein S-[2,3-bis(palmi-
toyloxy)-2(2-RS)-propyl]-N-palmitoyl-(R)-Cys-(S)-Ser-Lys-4-OH trihydrochloride
(Pam3Cys4) was obtained from InvivoGen and used at a final concentration of
200 ng/ml. CD40 ligand (CD40L) was obtained from PeproTech and used at a
final concentration of 250 ng/ml. Anti-six-His-horseradish peroxidase conjugates
were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-Flag
M2-horseradish peroxidase was obtained from Sigma. THP-1 cell lines stably
expressing empty vector (THP-EV), hemagglutinin (HA)-tagged wild-type (WT)
Monarch-1 (THP-WT) or shRNA targeting Monarch-1 (THP-shMon) have been
described previously (12, 27). The THP-1 cell line stably expressing HA-tagged
Monarch-1 containing the Walker A/B mutation (THP-mutA/B) was generated
by the same procedure.
Expression and purification of bacterial MBP–Monarch-1–NBD fusion pro-
tein. The cDNA sequence encoding amino acids 188 to 448 of Monarch-1 and
including the Walker A/B motifs was amplified by PCR using PFU Turbo poly-
merase (Stratagene). Restriction enzyme sites for HindIII and BamHI were
incorporated into the 5 and 3 ends of the PCR product, respectively. A DNA
sequence encoding a six-His tag was also introduced in the 3 reverse primer. The
amplified product was digested by HindIII and BamHI (New England BioLabs)
and cloned into the C terminus of the maltose binding protein (MBP) in the
vector pMAL-c2E (New England BioLabs). Mutations in both Walker A and
Walker B were generated by site-directed mutagenesis (Stratagene). All con-
structs were confirmed by DNA sequencing. The MBP–Monarch-1–NBD fusion
plasmids were transformed into the Escherichia coli strain Rosetta-Origami B
(EMD Biosciences). One liter of LB with 100 g/ml ampicillin was inoculated
with 5 ml of an overnight bacterial culture. The culture was grown at 37°C to an
A600 of 0.8, and then isopropylthio--D-galactoside (IPTG) was added to a final
concentration of 0.3 mM to induce the expression of the MBP fusion proteins.
After 3 h of induction at 25°C, the cells were harvested by centrifugation at 6,000
rpm. Cell pellets were washed once with cold phosphate-buffered saline and
resuspended in ice-cold lysis buffer (50 mM Tris-HCl [pH 7.6], 150 mM NaCl, 1
mM EDTA, 10 mM -mercaptoethanol, and Roche protease inhibitor cocktail).
Resuspension was facilitated by sonication for 2 min. Bacteria were then lysed
with recombinant lysozyme (EMD Biosciences) and then treated with benzonase
(EMD Biosciences) to degrade bacterial DNA and RNA. Bacterial lysates were
clarified by centrifugation twice at 15,000  g for 30 min. The supernatant was
filtered through a 0.2-m-pore-size low-protein binding filter. Amylose resin
(New England BioLabs) was washed twice with column buffer (20 mM Tris-HCl,
200 mM NaCl, 1 mM EDTA, 10 mM -mercaptoethanol) and added directly to
the bacterial lysate. The lysate-resin mix was rotated at 4°C for 1 h and then
transferred into an empty column. The resin was washed with 10 volumes of
column buffer and eluted with 5 volumes of column buffer containing 10 mM
maltose. The eluate containing MBP fusion protein was concentrated with an
Amicon centrifugal filter device. The partially purified MBP–Monarch-1–NBD
fusion proteins were further purified over a fast protein liquid chromatography
size exclusion column (Bio-Silect 400; Bio-Rad). Each fraction was tested for
nucleotide binding activity. The fractions with high nucleotide binding activity
were pooled and subsequently purified on a cobalt-based metal affinity column
(Sigma) and eluted with 300 mM imidazole.
Expression and purification of mammalian cell-derived Monarch-1LRR.
cDNA encoding Monarch-1 amino acids 1 to 686, which correspond to the pyrin
and NBD domains, was PCR amplified and cloned into the pCEP4 vector
(Invitrogen) by standard molecular cloning procedures. This expression con-
struct was introduced into the HEK293EBNA cell line (ATCC CRL10852) by
use of polyethyleneimine (Polyscience). The transfected HEK293EBNA cells
were then harvested and lysed in hypotonic lysis buffer (25 mM HEPES-KOH
[pH 7.5], 10 mM KCl, 5 mM MgCl2, 0.1 mM phenylmethylsulfonyl fluoride, and
Roche protease inhibitor cocktail) for 15 min on ice followed by a brief sonica-
tion for 40 seconds. Lysates were cleared by centrifugation at 20,000 rpm for 30
min and filtered through a 0.45-m-pore-size filter. The lysate was then subjected
to cobalt metal affinity resin purification (Clontech). The eluate was further
purified over an anti-Flag affinity matrix and eluted with excess Flag peptide
(Sigma). These eluates were resolved by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE), and proteins were visualized with Coomassie
blue stain.
Nucleotide binding assay. A rapid filter binding assay was developed to mea-
sure nucleotide binding to Monarch-1 fusion proteins. [-35S]ATP (1,250 Ci/
mmol) (Perkin Elmer Life and Analytical Sciences) was mixed with the indicated
amount of recombinant Monarch-1 in a final volume of 100 l of binding buffer
(50 mM Tris-HCl, 150 mM NaCl, 20 mM MgCl2, 2 mM dithiothreitol, 5%
glycerol, pH 7.5) and was incubated at 30°C for 1 h. After this incubation, the
samples were filtered through a 96-well nitrocellulose plate (Millipore) and
immediately washed twice with 200 l of ice-cold binding buffer by vacuum
filtration (Millipore). The filter plate was then air dried, and radioactivity was
measured using a scintillation counter. For homologous competition assays,
Monarch-1–NBD fusion protein (2 g) or Monarch-1LRR (450 ng) was incu-
bated with 90 nM [-35S]ATP and increasing concentrations of the indicated
unlabeled nucleotide. Homologous competitive binding curves represent nonlin-
ear regression fit to the single-site competition model [Y 	 Bottom  (Top 

Bottom)/(1  10X 
 logIC50), where IC50 is the 50% inhibitory concentration] using
GraphPad Prism 5 software. In homologous competitive binding assays, Kd
(dissociation constant) 	 IC50 
 [radioligand] (4).
ATPase assay. ATP hydrolysis was measured by visualizing the conversion of
[-32P]ATP to [-32P]ADP using thin-layer chromatography (TLC). A total of 5
g of purified Monarch-1LRR was incubated with 10 M ATP and 0.1 M
[-32P]ATP (3,000 Ci/mmol; Perkin Elmer Life and Analytical Science) in a total
volume of 40 l reaction buffer (25 mM Tris-HCl, pH 7.5; 150 mM NaCl; 10 mM
MgCl2; 1 mM dithiothreitol; 1 mM EDTA; 0.1 mM phenylmethylsulfonyl fluo-
ride) for 2 h. The reaction was quenched by adding an equal volume of TLC
development solvent (1 M formic acid, 0.5 M LiCl). A total of 2 l of the reaction
mixture was spotted on a polyethyleneimine cellulose TLC plate and developed
with 1 M formic acid with 0.5 M LiCl in a TLC chamber. The TLC plate was then
exposed to X-ray film.
Detection of cytokines and chemokines. The indicated THP-1-derived cells
lines were stimulated with 200 ng/ml Pam3Cys4 for 18 h and then 250 ng/ml
CD40L for an additional 5 h. The supernatant was applied to a RayBiotech
Human G series 2000 glass slide array and processed according to the manufac-
turer’s protocol. The signal strength for each cytokine was normalized to the
signal strength of a spiked, internal control for each slide. Normalized data for
each treatment group were then represented as a change compared to unstimu-
lated samples. For the data set from the array, see Tables S1 and S2 and Fig. S1
in the supplemental material. The array was performed for screening purposes,
and caution should be used when interpreting data not verified by enzyme-linked
immunosorbent assay (ELISA). For the ELISA studies, THP-1-derived cell lines
were stimulated as described above. Cytokine and chemokine levels in cell
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supernatants were analyzed by sandwich ELISA as recommended (R&D Sys-
tems).
Immunoprecipitation and Western blot analysis. HEK293T and THP-1 cell
lines, stimulated with the conditions indicated, were lysed in buffer containing
1% Triton X-100, 150 mM NaCl, 50 mM Tris-HCl (pH 8), 50 mM NaF, 2 mM
EDTA, plus a protease inhibitor cocktail (Roche). Immunoprecipitates were
washed four times in lysis buffer and eluted by boiling in reducing sample buffer.
Samples were fractionated by SDS-PAGE and transferred to nitrocellulose.
Western blots were probed with the indicated antibodies and then visualized
by enhanced chemiluminescence (Pierce) and exposure to photographic film
(Genesee Scientific). The films were scanned into Adobe Photoshop, and whole
images were adjusted for brightness. The images were cropped and formatted in
Adobe Illustrator. Nuclear/cytoplasmic fractions were prepared using the Pierce
NE-PER nuclear and cytoplasmic extraction reagent kit. The following antibod-
ies were used: anti-HA 12CA5 (Roche), anti-IRAK-1 (C-20), anti-NIK (H-248),
and anti-CagA (b-300, isotype control; Santa Cruz Biotechnology).
RESULTS
Enrichment and characterization of recombinant Mon-
arch-1. Initial attempts to express full-length Monarch-1 protein
using Escherichia coli and baculovirus expression systems failed to
yield a sufficient quantity of soluble protein for biochemical anal-
ysis despite extensive testing and optimization of expression con-
ditions and parameters. This is a common problem encountered
in the study of this family of proteins (14). Therefore, to improve
solubility, we employed an MBP expression system, in which
MBP was fused to the NBD of Monarch-1.
The NBD can be divided into a NACHT domain (NAIP,
CIITA, HET-E, and TP1) (11) and NACHT-associated do-
mains (NAD) (2). The NACHT domain of NLR proteins con-
tains well-conserved nucleotide binding structures, including
the ATP/GTP-specific phosphate binding loop called Walker
A and an Mg2 coordination site called Walker B (21, 25, 26).
We generated a fusion protein containing MBP fused to amino
acids 188 to 448 of Monarch-1 (Fig. 1A). In addition to the
N-terminal MBP moiety, a six-His tag was added to the C
terminus of the Monarch-1–NBD fusion proteins to facilitate
purification by dual-affinity chromatography. The region of
amino acids 188 to 448 of Monarch-1 comprises the NACHT
domain and NAD1. We predicted this region to have nucleo-
tide binding properties based upon the following: (i) the crystal
structure of the related dATP binding protein Apaf-1 and (ii)
a recent molecular modeling study in which the previously
FIG. 1. The generation and purification of Monarch-1–NBD fusion proteins. (A) Schematic diagram of domain structure of full-length
Monarch-1 and WT and mutA/B Monarch-1–NBD fusion proteins. The positions of the Walker A and Walker B motifs are depicted as solid bars
within the NACHT domain. The conserved amino acids within both motifs are shown, and the underlined residues were substituted with alanine
by site-directed mutagenesis. (B) WT Monarch-1–NBD and mut A/B Monarch-1–NBD were transformed into E. coli, and soluble bacterial extracts
were analyzed by SDS-PAGE and Coomassie blue staining. Arrowhead, Monarch-1–NBD fusion protein; U, uninduced; I, IPTG-induced. The
sizes of molecular weight markers (in thousands) are indicated on the left. (C) Bacterial lysates were passed over an amylose resin column targeting
MBP. Eluted proteins were resolved by SDS-PAGE and visualized with Coomassie blue stain. (D) Eluates from the amylose resin column were
further purified by size exclusion chromatography. The absorbance profile of size exclusion purification is depicted (upper panel), and the size
exclusion fractions were analyzed by SDS-PAGE and visualized by Coomassie blue staining (lower panel). (E) Western blots from size exclusion
fractions 17 to 21 were probed with an anti-MBP or anti-His antibody to verify the intactness of the N terminus and C terminus, respectively, of
the Monarch-1–NBD fusion protein. (F) Size exclusion fractions from WT or mutA/B Monarch-1–NBD were tested for ATP binding activity using
[-35S]ATP, and specific binding was normalized to the protein concentration of each fraction.
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broadly defined NBD domain was subdivided into the NACHT
domain and three subsequent NAD sequences (2).
NACHT domains consist of six -helices and a -sheet core
structure, which contains the highly conserved Walker A and
Walker B motifs responsible for nucleotide binding. The
Walker A motif contains the consensus sequence GXXGXG
K[T/S], wherein the conserved lysine residue is responsible for
the coordination of the - and -phosphate moieties of ATP.
The Walker B motif, DXXDE, contains two well-conserved
aspartic acid residues which are involved in the coordination of
Mg2 and ATP hydrolysis. To ensure the complete disruption
of nucleotide binding, mutations were introduced within both
the Walker A and Walker B motifs and will be referred to
hereafter as mutA/B.
Plasmids encoding the WT or mutA/B Monarch-1–NBD
fusion proteins were transfected into E. coli and were predom-
inantly expressed as soluble proteins with a molecular weight
of approximately 80,000 (Fig. 1B). An affinity-based amylose
resin targeting MBP was used to enrich the fusion proteins and
yielded a partially purified product (Fig. 1C). Although MBP
increases the solubility of its cargo protein, a large portion of
the fusion protein may remain in a misfolded, high-molecular-
weight soluble aggregate that is biochemically inactive. To sep-
arate functionally active protein from these soluble aggregates
and further purify the protein, we applied the amylose resin-
enriched product to a size exclusion column. Figure 1D depicts
the fast protein liquid chromatography elution profile of WT
Monarch-1–NBD and the Coomassie blue-stained SDS-PAGE
gel containing the size exclusion fractions. The mutA/B Mon-
arch-1–NBD fusion protein exhibited expression and chro-
matographic profiles identical to those of the WT protein (data
not shown). A large percentage of the protein (70 to 80%)
eluted in fractions 12 to 14. These fractions consisted of the
excluded volume of the column (700,000) and represent pro-
teins existing in a high-molecular-weight aggregation state.
Fractions 15 to 19 contained the Monarch-1–NBD fusion pro-
tein existing in lower-molecular-weight states (80,000 to
300,000), which likely represented monomeric, dimeric, and
trimeric complexes. Fractions 20 to 22 contained degradative
products (Fig. 1D). The presence of intact Monarch-1–NBD
was confirmed by Western blot analysis of fractions 17 to 21
using antibodies against N-terminal MBP and C-terminal
six-His (Fig. 1E). The MBP antibody detected full-length Mon-
arch-1–NBD protein as well as lower-molecular-weight moi-
eties. The anti-six-His antibody detected only full-length Mon-
arch-1–NBD proteins. This suggests that the smaller moieties
detected by the MBP antibody in fractions 20 to 21 were likely
MBP fusion proteins missing an intact C terminus.
To determine if the gel filtration fractions contained bio-
chemically active Monarch-1–NBD, an ATP binding assay was
performed. In this assay, recombinant proteins from each frac-
tion were incubated with radiolabeled [-35S]ATP, a nonhy-
drolysable ATP analog, and then loaded onto a nitrocellulose
filter plate. Protein-bound nucleotides were trapped on the
membrane, while free nucleotides passed through the mem-
brane by repeated buffer washes. Fractions 12 to 14, corre-
sponding to the high-molecular-weight aggregates, exhibited
poor ATP binding activity (Fig. 1F). This suggests that these
high-molecular-weight soluble aggregates of Monarch-1–NBD
likely remained in a misfolded, inactive state. In contrast, ATP
binding activity significantly increased in the lower-molecular-
weight fractions, with fractions 18 and 19 exhibiting the highest
ATP binding activity. To assess if the Walker A and B motifs
are required for nucleotide binding, we performed this ATP
binding assay using size exclusion chromatography fractions
containing mutA/B Monarch-1-NBD. Mutations within the
Walker A/B sequences dramatically reduced the nucleotide
binding activity of the protein (Fig. 1F), demonstrating their
importance for Monarch-1 nucleotide binding. The greatest
difference was observed in fraction 19, where the ATP binding
activity of WT Monarch-1–NBD was fivefold higher than that
of the corresponding mutA/B form of the protein. Together,
these results indicate that Monarch-1 binds ATP and that the
Walker A/B motifs are required for nucleotide binding.
Monarch-1 specifically binds ATP. To more accurately de-
termine both the affinity and specificity of ATP binding, we
further purified WT Monarch-1–NBD by taking advantage of
the C-terminal six-His tag. Fractions 18 and 19, which demon-
strated the highest level of nucleotide binding (Fig. 1F), were
pooled and applied to a cobalt-based metal affinity purification
column. The resulting product was highly enriched and mi-
grated as a single band at 80,000 as examined by Coomassie
blue staining (Fig. 2A). To determine the affinity of ATP bind-
ing, highly enriched WT Monarch-1–NBD was incubated with
radiolabeled [-35S]ATP along with increasing concentrations
of unlabeled [-S]ATP. The dissociation constant (Kd) of
[-35S]ATP binding was determined to be 100 nM (Fig. 2B).
Next we tested the nucleotide binding preference of WT Mon-
arch-1–NBD. The fusion protein was preincubated with radio-
labeled [-35S]ATP for 2 h, and then unlabeled [-S]ATP,
ATP, GTP, or CTP was added to compete for WT Monarch-
1–NBD binding. Unlabeled [-S]ATP and ATP successfully
competed with radiolabeled [-35S]ATP (Fig. 2C). However,
even at this high nucleotide concentration, GTP and CTP
displayed only a slight ability to compete with [-35S]ATP. This
strongly suggests that WT Monarch-1–NBD specifically binds
ATP.
Recombinant Monarch-1 derived from mammalian cells
binds ATP. The experiments described above employed WT
Monarch-1–NBD fusion proteins derived from bacteria to
demonstrate ATP binding activity. However, these fusion pro-
teins lacked the N-terminal pyrin domain and C-terminal LRR
domain found in the full-length protein. The crystal structure
of Apaf-1 indicates that its N-terminal effector domain folds
back on the ATP binding pocket within the NBD (9). Although
this does not affect dATP binding by Apaf-1, this observation
led us to question if the pyrin domain or the LRR domain of
Monarch-1 affects nucleotide binding.
To determine the influence of these domains on ATP bind-
ing activity, we purified full-length Monarch-1 using a mam-
malian expression system. In order to enhance protein expres-
sion, we employed an Epstein-Barr virus-based episomal
replication system. Sequences encoding the WT and mutA/B
Monarch-1 were cloned into Epstein-Barr virus expression vec-
tors, and an N-terminal 10-His tag and a C-terminal Flag tag
were added to facilitate dual-affinity purification. Again, we
were unable to obtain sufficient quantities of full-length Mon-
arch-1. However, soluble Monarch-1 protein was successfully
obtained after deleting the LRR domain (Monarch-1LRR)
(Fig. 3A). The WT and mutA/B Monarch-1LRR were first
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partially purified by cobalt metal affinity. The recombinant
proteins in this eluate were then further purified by anti-Flag
affinity chromatography. Coomassie blue staining along with
anti-His and anti-Flag Western blotting revealed a single band
that corresponded to the purified WT and mutA/B Monarch-
1LRR (Fig. 3B and C).
To determine if Monarch-1LRR exhibited nucleotide
binding activity, an ATP binding assay was performed. As seen
in the bacterial expression system, purified WT Monarch-
lLRR exhibited strong ATP binding activity, while this bind-
ing activity was dramatically reduced in the mutA/B form of
the protein (Fig. 3D). Nucleotide competition assays deter-
mined the binding affinity to be 84 nM (Fig. 3E). This was
comparable to the binding affinity observed for the WT Mon-
arch-1–NBD fusion protein derived from bacterial expression.
In addition, similar to the bacterium-derived WT Monarch-1–
NBD fusion protein, unlabeled ATP successfully competed for
[-35S]ATP binding (Fig. 3F). Unlabeled CTP and GTP, how-
ever, demonstrated only a slight ability to compete for
[-35S]ATP at 100-fold higher concentrations of nucleotide.
Together, these results demonstrate that Monarch-1 specifi-
cally binds ATP.
Recombinant Monarch-1 derived from mammalian cells
possesses ATPase activity. To determine if WT Monarch-
1LRR possessed ATP hydrolysis activity, the purified protein
was incubated with radiolabeled [-32P]ATP and the reaction
mixture was analyzed by TLC. Whole-cell lysate was used as a
positive control to show the conversion of radiolabeled ATP to
ADP, while bovine serum albumin, a non-ATPase, was used as
a negative control. Purified WT Monarch-1LRR exhibited
ATPase activity as shown by the conversion of ATP to ADP
(Fig. 3G). In contrast, the mutA/B Monarch-1LRR construct
which bears the Walker A/B mutations did not exhibit ATPase
activity. Together, these results clearly demonstrate that Mon-
arch-1 binds ATP and possesses ATPase activity; however, we
have not been able to separate these two activities at this point.
Nucleotide binding regulates Monarch-1 self association.
The oligomerization of NLR proteins has been shown to be
important for their activity (6, 13). To determine if nucleotide
binding is required for Monarch-1 self association, Flag-tagged
WT Monarch-1 was cotransfected into HEK293T cells along
with HA-tagged WT Monarch-1 or HA-tagged mutA/B Mon-
arch-1. Protein complexes were immunoprecipitated with anti-
Flag antibody, and Western blots were probed with anti-HA to
detect self-associating, homomeric Monarch-1 complexes. As
expected, WT Monarch-1 exhibited self association, as HA-
tagged WT Monarch-1 coprecipitated with Flag-tagged WT
Monarch-1 (Fig. 4, lane 3). In addition, WT Monarch-1 also
associated with mutA/B Monarch-1, as HA-tagged forms of
the NBD mutant were detected in WT Monarch-1 precipitates
(Fig. 4, lane 4). Interestingly, however, when Flag-tagged and
HA-tagged forms of mutA/B Monarch-1 were coexpressed,
they failed to form homomeric complexes, as HA-tagged
mutA/B Monarch-1 was not detected in anti-Flag immunopre-
cipitates (Fig. 4, lane 5). Together, these results suggest that
complex formation among Monarch-1 molecules requires nu-
cleotide binding but that not every member of the complex
must bind nucleotides. This phenomenon was also observed
for the NLR protein, CIITA, suggesting that it may be a com-
mon feature of NLR proteins (13).
Nucleotide binding regulates the ability of Monarch-1 to
inhibit NIK activity. Recently, we demonstrated that Mon-
arch-1 suppresses the activation of noncanonical NF-B by
associating with NIK. To determine the role of nucleotide
binding in the formation of this molecular complex, HEK293
cells were cotransfected with NIK and full-length forms of
HA-tagged WT or mutA/B Monarch-1. Cell lysates were im-
munoprecipitated with anti-NIK antibodies, and Western blots
were probed with anti-HA antibody to detect Monarch-1. As
previously reported, WT Monarch-1 coprecipitated with NIK
(Fig. 5A). Similarly, mutA/B Monarch-1 also associated with
FIG. 2. Purified Monarch-1–NBD fusion protein specifically binds
ATP. (A) Gel filtration fractions 18 to 19 (depicted in Fig. 1) were
pooled and further purified by cobalt metal affinity chromatography.
The purity of the final purification product was assessed by SDS-PAGE
and Coomassie blue staining. Arrowhead, Monarch-1–NBD fusion
protein. The sizes of molecular weight markers (in thousands) are
indicated on the left. (B) Homologous competition assays were per-
formed to assess the ATP binding affinity of Monarch-1–NBD.
(C) Specificity of ATP binding was determined by incubating Mon-
arch-1–NBD fusion protein with [-35S]ATP and 10 M of the indi-
cated unlabeled competitor nucleotide. Significance of the difference
from control samples was estimated by Student’s t test. “None” indi-
cates no nucleotide. A double asterisk signifies a P value of 0.000003.
A single asterisk signifies a P value of 0.011 for GTP or 0.0085 for CTP.
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NIK, suggesting that nucleotide binding is not a requirement
for complex formation in this overexpression model. To fur-
ther assess the role of nucleotide binding in Monarch-NIK
complex formation, THP-1 monocytes stably expressing HA-
tagged WT or mutA/B Monarch-1 were treated with CD40L to
induce the activation of endogenous NIK. Cell extracts were
immunoprecipitated with anti-NIK antibodies, and Western
blot analyses were performed to detect coprecipitating Mon-
arch-1. As previously described, CD40L treatment enhanced
the association of WT Monarch-1 with endogenous NIK (Fig.
FIG. 3. Mammalian cell-derived recombinant Monarch-1LRR binds and hydrolyzes ATP. (A) Diagram depicting full-length Monarch-1 and
the WT and mutA/B Monarch-1LRR proteins produced in HEK293EBNA cells. (B) Soluble extracts of HEK293EBNA cells expressing WT and
mutA/B Monarch-1LRR were enriched for Monarch-1LRR using a cobalt metal affinity column (lanes 1 and 2) and further purified over an
anti-Flag affinity matrix (lanes 3 and 4). The purity was evaluated by Coomassie blue staining. The sizes of molecular weight markers (in thousands)
are indicated on the left. (C) The double-purified Monarch-1LRR proteins were analyzed by Western blotting using anti-His and anti-Flag
antibodies. (D) ATP binding activity of purified WT and mutA/B Monarch-1LRR was determined by incubating 500 ng purified protein with
[-35S]ATP. Error bars represent the standard deviations of ATP binding measurements in triplicate. (E) The ATP binding affinity of WT
Monarch-1LRR was determined by homologous competition binding assays. (F) The nucleotide binding preference of WT Monarch-1LRR was
determined by incubating WT Monarch-1LRR with [-35S]ATP and increasing concentrations of unlabeled nucleotide. Significance of the
differences from control samples (nucleotide concentrations of 10
9 M) was estimated by Student’s t test. A double asterisk signifies a P value of
0.0005. A single asterisk signifies a P value of 0.02. (G) The ATPase activity of purified WT or mutA/B Monarch-1LRR was measured by
visualizing the conversion of [-32P]ATP to [-32P]ADP by TLC. HEK293EBNA lysate and purified bovine serum albumin (BSA) were used as
positive and negative controls, respectively. Arrowhead, Monarch-1-NBD fusion protein.
1846 YE ET AL. MOL. CELL. BIOL.
5B). In contrast, the association between mutA/B Monarch-1
and NIK failed to increase upon activation. Thus, while nucle-
otide binding is not an absolute requirement for NIK binding,
it is required for activation-induced complex formation.
NIK activates noncanonical NF-B by inducing proteolytic
processing of NF-B2/p100 to p52. This smaller active form of
NF-B2 rapidly translocates to the nucleus to regulate the
transcription of inflammatory genes. In contrast, the unproc-
essed form, p100, functions as an inhibitor of NF-B activity
(17). We recently demonstrated that the association of Mon-
arch-1 with NIK results in the suppression of p100 processing.
To determine the role of nucleotide binding in this function,
THP-1 monocytes expressing an empty vector, WT Monarch-1,
or mutA/B Monarch-1 were stimulated via TLR2 to induce
p100 expression. The cells were then treated with CD40L to
induce NIK-dependent p100 processing. As previously re-
ported, WT Monarch-1 suppressed p100 processing, as dem-
onstrated by a sharp reduction in nuclear p52 in THP-WT
Monarch-1 cells (Fig. 5C, lane 4). Moreover, this reduction in
nuclear p52 occurred in the presence of elevated levels of
cytoplasmic p100 in these cells. Finally, the accumulation of
p100 in the nucleus was consistently detected in THP-WT
Monarch-1 cells, further emphasizing the role of Monarch-1 in
inhibiting p100 processing. In contrast to WT Monarch-1,
mutA/B Monarch-1 did not affect CD40L-induced activation
of noncanonical NF-B, as nuclear p52 levels were comparable
to those seen in control THP-EV cells. Thus, consistent with
the inability of mutA/B Monarch-1 to bind NIK following
activation, the NBD mutant did not inhibit p100 processing.
These results demonstrate that nucleotide binding is required
for Monarch-1 to suppress noncanonical NF-B.
Nucleotide binding regulates the ability of Monarch-1 to
inhibit IRAK-1 activation. In addition to NIK, we have also
shown that upon TLR stimulation, Monarch-1 binds IRAK-1
and inhibits its hyperphosphorylation (27). To determine if
nucleotide binding is required for the association of Mon-
arch-1 with IRAK-1, THP-1 cells expressing WT or mutA/B
Monarch-1 were stimulated with the TLR2 agonist, Pam3Cys4.
Endogenous IRAK-1 complexes were captured by immuno-
precipitation, and Western blot analyses were performed to
detect Monarch-1. In agreement with our previous findings,
the complex formation between WT Monarch-1 and IRAK-1
strengthened upon TLR stimulation (Fig. 6A). However, sim-
ilar to NIK, mutA/B Monarch-1 associated more strongly with
IRAK-1 in resting cells, and activation-induced association was
abrogated by Walker A/B mutations. Accordingly, TLR2 stim-
ulation resulted in the hyperphosphorylation of IRAK-1 in
THP-mutA/B Monarch-1 at levels comparable to those of con-
FIG. 4. Nucleotide binding is required for Monarch-1 self associa-
tion. HEK293T cells were transfected with full-length forms of HA- or
Flag-tagged WT or mutA/B Monarch-1. Flag-tagged proteins were
immunoprecipitated (IP) with an anti-Flag antibody, and Western
blots (IB) were probed with anti-HA antibody to detect self-associated
Monarch-1.
FIG. 5. Nucleotide binding is required for Monarch-1 to suppress
NIK-mediated p100 processing. (A) HEK293T cells were cotransfected
with NIK and HA-tagged WT or mutA/B Monarch-1. Cell lysates were
immunoprecipitated (IP) with anti-NIK antibodies, and Western blots
(IB) were probed with anti-HA antibodies to detect Monarch-1. ctrl lg,
isotype control antibody. (B) THP-WT or THP-mutA/B cells were stim-
ulated with CD40L for indicated times. Endogenous NIK was immuno-
precipitated, and Western blots were probed with anti-HA to detect
coprecipitating Monarch-1. Control immunoprecipitations were per-
formed with an isotype control antibody to monitor specificity. Control
Western blottings were performed to monitor the expression of Mon-
arch-1 and NIK in cellular lysates. (C) THP-EV, THP-WT, or THP-
mutA/B cells were stimulated with Pam3Cys4 for 18 h to induce p100
expression. The cells were then treated with CD40L for an additional 5 h
to induce p100 cleavage to p52. Cells were fractionated into nuclear and
cytoplasmic fractions, and proteins from each fraction were separated by
SDS-PAGE. Western blots were probed with anti-p100 to detect p100
and its cleaved form, p52. Anti-HA was used to monitor Monarch-1
expression. These results are representative of at least five separate ex-
periments.
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trol THP-EV cells (Fig. 6B). In agreement with our previous
findings, WT Monarch-1 suppressed the accumulation of these
hyperphosphorylated forms of IRAK-1 (Fig. 6B) (12). These
data confirm the requirement for nucleotide binding in Mon-
arch-1-mediated suppression of inflammatory signaling.
Nucleotide binding regulates the anti-inflammatory activity
of Monarch-1. Previously, we demonstrated that Monarch-1
suppresses the production of proinflammatory cytokines and
chemokines in stimulated monocytic cells (12, 27). To deter-
mine the role of nucleotide binding in this anti-inflammatory
activity, THP-1 cells stably expressing full-length WT or
mutA/B Monarch-1 were stimulated, and supernatants were
applied to a cytokine/chemokine antibody array. THP-1 cells
stably transfected with empty vector (THP-EV) were used as
controls. In agreement with our previous reports, THP-1 cells
expressing WT Monarch-1 produced lower levels of inflamma-
tory cytokines and chemokines than those of the THP-EV
control samples. These included IL-6 and CXCL13, which
have been previously shown to be suppressed by WT Mon-
arch-1 (see Fig. S1 in the supplemental material) (12, 27). In
contrast, THP-1 monocytes expressing mutA/B Monarch-1
produced increased levels (more than twofold) of these pro-
teins compared to control samples (see Fig. S1 in the supple-
mental material). A large number of cytokines and chemokines
were not substantially induced by Pam3Cys4/CD40L stimula-
tion (see Table S1 in the supplemental material). Another set
of proteins was increased less than twofold in THP-1 cells
expressing mutA/B compared to control cells and was not
further investigated (see Table S2 in the supplemental mate-
rial).
Of the 79 cytokines and chemokines examined, we found the
greatest differences in IL-6, CXCL6, and CXCL13 (Fig. 7). To
confirm these results from the array, we performed ELISAs.
For these experiments, THP-1 cells expressing shRNA target-
ing endogenous Monarch-1 (THP-shMon) were included. As
expected, the expression of WT Monarch-1 resulted in the
decreased production of IL-6, CXCL13, and CXCL6 com-
pared to THP-EV cells (Fig. 7). In contrast, elevated levels of
these cytokines/chemokines were detected in supernatants
from THP-shMon cells, confirming our earlier reports demon-
strating that silencing endogenous Monarch-1 results in a hy-
perinflammatory response (12, 27). Similar to THP-shMon
cells, THP-mutA/B Monarch-1 cells also produced increased
levels of these inflammatory mediators. These results demon-
strate that nucleotide binding is required for the anti-inflam-
matory activity of Monarch-1. In addition, these results suggest
that the presence of a nucleotide binding-deficient form of
Monarch-1 can block the activity of endogenous Monarch-1.
DISCUSSION
Despite the general perception that members of the NLR
family function as nucleotide binding proteins, this property
has not been extensively studied. One group has shown data
derived from plant R proteins that demonstrate the nucleotide
FIG. 6. Nucleotide binding by Monarch-1 is required for the sup-
pression of IRAK-1 hyperphosphorylation. (A) THP-WT or THP-
mutA/B cells were stimulated for the indicated times with Pam3Cys4.
Endogenous IRAK-1 was immunoprecipitated (IP), and Western blots
(IB) were probed with anti-HA to detect Monarch-1. Control samples
were immunoprecipitated with an isotype-matched antibody. Control
Western blottings were performed on cellular lysates to monitor the
levels of Monarch-1 and IRAK-1. (B) THP-EV, THP-WT, and THP-
mutA/B cells were stimulated with Pam3Cys4 for the indicated times.
Lysates were separated by SDS-PAGE, and Western blots were
probed with anti-IRAK-1 antibodies. Control Western blottings were
performed and probed with anti-HA to monitor Monarch-1 expres-
sion. These results are representative of at least five separate experi-
ments.
FIG. 7. Nucleotide binding is required for Monarch-1-mediated suppression of proinflammatory cytokine and chemokine production. THP-EV,
THP-WT, THP-mutA/B, and THP-shMon were stimulated with Pam3Cys4 for 18 h and then CD40L for an additional 5 h. Cell culture
supernatants were harvested, and cytokine/chemokine levels determined by ELISA.
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binding properties of these proteins (23). Furthermore, despite
this lack of convincing data, the assumption has been that
nucleotide binding is required for the function of these pro-
teins. This concept is largely modeled after the analysis of
Apaf-1 (9). Thus, a key finding in this report is that highly
enriched Monarch-1 specifically binds ATP, and this is re-
quired for its anti-inflammatory activity. Monarch-1 is also
unique in that it functions as a brake on innate immune acti-
vation, as opposed to several of the other NLR proteins.
The requirement of nucleotide binding for Monarch-1 ac-
tivity supports a recent report by our group that focused on the
NLR protein cryopyrin/NLRP3. In that report, we demon-
strated that NLRP3 binds ATP and that this binding activity is
required for NLRP3-mediated IL-1 processing (4). Prior to
these studies, only two other reports suggested nucleotide
binding as a regulatory step in NLR function. An earlier report
from our group suggested that CIITA binds GTP and that
mutations within the Walker A/B motifs block CIITA-medi-
ated transcriptional activation. In that study, however, nucle-
otide binding assays were performed by analyzing CIITA pro-
teins that had been immunoprecipitated from transfected cells.
Since CIITA forms large protein complexes, the nucleotide
binding activities of coprecipitating proteins could not be ruled
out. More recently, glutathione S-transferase fusion proteins
containing the NBD of the NLR protein IPAF were shown to
bind ATP (14). Mutations with the Walker A motif of IPAF
result in reduced caspase-1 activity. However, similar to the
CIITA study, protein purity remains an issue in this study.
In this report, we produced highly enriched Monarch-1 fu-
sion proteins derived from both prokaryotic and eukaryotic
expression systems to conclusively demonstrate the nucleotide
binding activity of Monarch-1. The importance of Monarch-1
nucleotide binding in suppressing NF-B activation and in-
flammatory signaling has been clearly demonstrated in this
report. Expression of a nucleotide binding-deficient form of
Monarch-1 (mutA/B Monarch-1) in monocytes resulted in dra-
matically increased production of proinflammatory mediators.
These levels were comparable to those observed in THP-
shMon cells in which endogenous Monarch-1 expression was
silenced. This hyperinflammatory phenotype of cells express-
ing mutA/B Monarch-1 correlates well with the inability of this
mutant to suppress NF-B2/p100 processing and the inability
of this mutant to efficiently bind NIK and IRAK-1 following
stimulation.
Interestingly, an association was detected between these ki-
nases and mutA/B Monarch-1 in resting cells. This suggests
that the mutations within the Walker A/B sequences are subtle
enough not to disrupt complex formation in resting cells but
render Monarch-1 unable to bind these kinases upon stimula-
tion. This loss of activation-induced NIK and IRAK-1 binding
by mutA/B Monarch-1 may be due to its inability to form
homomeric structures, a property required for the activity of
CIITA, APAF-1, and NALP3. A second possibility relates to
the functional dissection of ATP binding and ATP hydrolysis.
For instance, it has been reported that ATP binding is required
for the activity of the plant R protein I-2, yet the hydrolysis of
this bound ATP moiety suppresses I-2 function (23, 24). Thus,
the binding and hydrolysis of ATP may represent an on-off
switch of NLR protein function. Future studies will be con-
ducted to fully characterize the ATP hydrolysis cycle of Mon-
arch-1 and to determine its contribution to the anti-inflamma-
tory role of Monarch-1.
Despite exhaustive attempts to optimize conditions, we were
not able to produce sufficient quantities of soluble, full-length
purified protein. Instead, we generated recombinant Mon-
arch-1 in mammalian cells by deleting the LRR domain. Thus,
while it is clear that Monarch-1 binds ATP, it remains uncer-
tain whether or not the LRR domain regulates this activity. In
our recent report describing ATP binding by cryopyrin, puri-
fied proteins contained intact LRR sequences and these do-
mains did not affect ATP binding. Therefore, due to the se-
quence similarities between Monarch-1 and NALP3, it is
unlikely that the LRR domain disrupts nucleotide binding.
The nucleotide binding property of NLRs lends these pro-
teins to pharmacologic intervention, as there are abundant
nucleotide and nucleoside analog libraries available for drug
screening. Thus, there now emerges the possibility of screening
for nucleotide analogs that can bind to Monarch-1, cause sus-
tained blockage of its function, and potentiate innate immune
responses. In summary, our work demonstrates that Mon-
arch-1 is an ATP binding protein and that this ATP binding
activity is essential for Monarch-1 to perform its inhibitory role
in innate immune signaling.
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